# DMC Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dmc-bio

- Industry: Biotechnology
- Headquarters: Boulder, US
- Website: www.dmcbio.com
- Total disclosed funding: $44M
- Latest round: Series B (Dec 2, 2021)
- Investors on record: 9

## About

DMC Bio, Inc. is a biotechnology company focused on creating sustainable, bio-based chemicals through precision fermentation technology, aiming to meet the rising demand for eco-friendly ingredients across various industries.Founded in 2014 and headquartered in Boulder, US, DMC Bio, Inc. specializes in the development of bio-based chemicals through innovative fermentation processes. The company has raised a total of USD 34.00 mn in its most recent funding round, a Series B led by ADM Capital, with participation from notable investors like Boulder Ventures and Michelin Ventures. This funding will support their mission to provide sustainable alternatives for manufacturers. The company was founded by Matt Lipscomb, who has a history of involvement in the biotechnology sector.DMC Biotechnologies specializes in the development and commercialization of sustainable, bio-based chemicals through precision fermentation, utilizing their proprietary Dynamic Metabolic Control™ technology. Their core product offerings include L-alanine and fermented myo-inositol, designed to meet the growing demands for environmentally responsible ingredients in various industries, such as dietary supplements, nutraceuticals, and cosmetic actives. DMC's L-alanine production process significantly reduces CO2 emissions, making it an eco-friendly choice for manufacturers. The company’s products are marketed primarily in North America and Asia, targeting companies that prioritize sustainability and innovation in their supply chains.DMC Biotechnologies generates revenue through direct partnerships and collaborations with a range of businesses, focusing on B2B transactions. Their revenue model includes long-term agreements for the supply of their bio-based chemicals, allowing clients to integrate these ingredients into their own product offerings. The company's flagship products, such as the fermented myo-inositol, are offered to health brands and manufacturers at competitive pricing, facilitating broad adoption within the marketplace. Revenue streams are bolstered by ongoing collaborations, including a multi-year agreement with Toyobo Co., Ltd., aimed at developing sustainable fermentation-produced chemical intermediates.In December 2021, DMC Bio, Inc. raised USD 34.00 mn in Series B funding to accelerate the commercialization of economically attractive and sustainable choices for consumers. The company plans to design and launch new sustainable products in the upcoming years, while also targeting expansion into additional markets in North America and Asia by 2023. The recent funding will be directed towards enhancing their production capabilities and increasing their market reach, ensuring they meet the evolving demands of their client base.

## Funding rounds

- Series B, Dec 2, 2021, $34M — Capricorn Partners, Sofinnova Partners, Boulder Ventures, ADM Capital, Breakthrough Energy Ventures, Toyobo, Michelin Ventures, Solvay Ventures, Siam Cement Public Company Limited
- Series A, Jul 9, 2019, $10M — Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures

## Investors

- Capricorn Partners (https://capitalatlas.ai/funds/capricorn-partners) — Series A, Series B
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Breakthrough Energy Ventures (https://capitalatlas.ai/funds/breakthrough-energy-ventures) — Series A, Series B
- Boulder Ventures (https://capitalatlas.ai/funds/boulder-ventures) — Series B
- ADM Capital — Series B
- Toyobo — Series B
- Michelin Ventures — Series B
- Solvay Ventures — Series B
- Siam Cement Public Company Limited — Series B